Hybrigenics Société Anonyme, a bio-pharmaceutical company, focuses on the research and development of various therapies against proliferative diseases.
+ 2 more risks
Mediocre balance sheet with weak fundamentals.
Share Price & News
How has Hybrigenics Société Anonyme's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 3HB's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 3HB underperformed the German Biotechs industry which returned 5.3% over the past year.
Return vs Market: 3HB underperformed the German Market which returned 17.1% over the past year.
Price Volatility Vs. Market
How volatile is Hybrigenics Société Anonyme's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Hybrigenics Société Anonyme undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 3HB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 3HB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 3HB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 3HB is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 3HB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 3HB is overvalued based on its PB Ratio (11.8x) compared to the DE Biotechs industry average (3.4x).
How is Hybrigenics Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hybrigenics Société Anonyme has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of 3HB’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Hybrigenics Société Anonyme competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Hybrigenics Société Anonyme performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 3HB is currently unprofitable.
Growing Profit Margin: 3HB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 3HB is unprofitable, and losses have increased over the past 5 years at a rate of -32.3% per year.
Accelerating Growth: Unable to compare 3HB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 3HB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).
Return on Equity
High ROE: 3HB has a negative Return on Equity (-1760.56%), as it is currently unprofitable.
How is Hybrigenics Société Anonyme's financial position?
Financial Position Analysis
Short Term Liabilities: 3HB's short term assets (€6.2M) exceed its short term liabilities (€6.0M).
Long Term Liabilities: 3HB has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 3HB's debt to equity ratio (23.5%) is considered satisfactory.
Reducing Debt: 3HB's debt to equity ratio has increased from 20.4% to 23.5% over the past 5 years.
Inventory Level: 3HB has a low level of unsold assets or inventory.
Debt Coverage by Assets: 3HB's debt is covered by short term assets (assets are 62x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if 3HB has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 3HB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Hybrigenics Société Anonyme's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 3HB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 3HB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 3HB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 3HB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 3HB's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rémi Delansorne (60yo)
Dr. Rémi Delansorne, D.V.M, Ph.D. serves as the Chief Executive Officer of Hybrigenics. Dr. Delansorne has been the Chief Executive Officer and Chairman of Hybrigenics Société Anonyme (alternate name, Hybr ...
CEO Compensation Analysis
Compensation vs Market: Rémi's total compensation ($USD0.00) is below average for companies of similar size in the German market ($USD425.50K).
Compensation vs Earnings: Rémi's compensation has been consistent with company performance over the past year.
|Chairman & CEO||14.08yrs||€420.12k||no data|
|CFO & Financial Director||11.33yrs||no data||no data|
|Human Resources Director||8.75yrs||no data||no data|
|Senior Director and Head of Clinical R&D||no data||no data||no data|
Experienced Management: 3HB's management team is seasoned and experienced (11.3 years average tenure).
|Chairman & CEO||14.08yrs||€420.12k||no data|
|Independent Director||no data||€30.00k||no data|
|Independent Director||6.83yrs||€30.00k||no data|
|Independent Director||4.25yrs||€30.00k||no data|
Experienced Board: 3HB's board of directors are considered experienced (6.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.5%.
Hybrigenics Société Anonyme's company bio, employee growth, exchange listings and data sources
- Name: Hybrigenics Société Anonyme
- Ticker: 3HB
- Exchange: DB
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €5.021m
- Shares outstanding: 46.75m
- Website: https://www.hybrigenics.com
Number of Employees
- Hybrigenics Société Anonyme
- 3-5 impasse Reille
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ALHYG||ENXTPA (Euronext Paris)||Yes||Common Stock||FR||EUR||Dec 2007|
|3HB||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Dec 2007|
|3HB||BST (Boerse-Stuttgart)||Yes||Common Stock||DE||EUR||Dec 2007|
Hybrigenics Société Anonyme, a bio-pharmaceutical company, focuses on the research and development of various therapies against proliferative diseases. Its development program is based on inecalcitol, a vitamin D receptor for the treatment of cancers, such as chronic lymphocytic leukemia, chronic myeloid leukemia, acute myeloid leukemia, and prostate cancer. The company was founded in 1997 and is headquartered in Paris, France.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/10/15 21:02|
|End of Day Share Price||2019/10/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.